Search results for " Continuous Ambulatory"

showing 7 items of 7 documents

Continuous ambulatory peritoneal dialysis as a therapeutic alternative in patients with advanced congestive heart failure.

2012

Aims Continuous ambulatory peritoneal dialysis (CAPD) has been proposed as an additional therapeutic resource for patients with advanced congestive heart failure (CHF). The objective of this study was to determine the therapeutic role of CAPD, in terms of surrogate endpoints, in the management of patients with advanced CHF and renal dysfunction. A total of 57 candidates with New York Heart Association (NYHA) class III/IV CHF, renal dysfunction (glomerular filtration rate , 60 mL/min/1.73 m 2 ), persistent fluid congestion despite loop diuretic treatment, and at least two previous hospitalizations for acute heart failure (AHF) were invited to be included in the CAPD programme; however, 25 pa…

Malemedicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentRenal functionurologic and male genital diseasesKidneySeverity of Illness IndexPeritoneal dialysisPeritoneal Dialysis Continuous AmbulatoryInternal medicineSurveys and QuestionnairesmedicineAmbulatory CareHumanscardiovascular diseasesProspective StudiesRenal InsufficiencyProspective cohort studyHeart Failurebusiness.industrySurrogate endpointContinuous ambulatory peritoneal dialysisLoop diureticBrain natriuretic peptidemedicine.diseaseHeart failureCardiologyFemaleCardiology and Cardiovascular MedicinebusinessBiomarkersGlomerular Filtration RateEuropean journal of heart failure
researchProduct

Importance of Residual Renal Function in Continuous Ambulatory Peritoneal Dialysis: Its Influence on Different Parameters of Renal Replacement Treatm…

1999

<i>Objective:</i> To study the influence of residual renal function (RRF) on different parameters of the renal substitutive treatment offered by peritoneal dialysis. <i>Methods:</i> We analyzed the impact of RRF on dialysis dose, nutrition parameters, anemia and phosphocalcic metabolism in 37 patients with end-stage renal disease (ESRD) treated by continuous ambulatory peritoneal dialysis (CAPD). Analytical controls were done every 6 months after an initial assessment at the end of the first month of treatment. Multiple lineal regression models were used as the statistical method to analyze the influence of RRF on different theoretically dependent factors. RRF was ca…

medicine.medical_specialtymedicine.medical_treatmentUrologyRenal functionKidneyKidney Function Testsurologic and male genital diseasesPeritoneal dialysisPhosphorus metabolismHemoglobinsPeritoneal Dialysis Continuous AmbulatoryDialysis SolutionsmedicineHumansRetrospective Studiesbusiness.industryContinuous ambulatory peritoneal dialysisAnemiaPhosphorusRetrospective cohort studymedicine.diseaseSurgeryNutrition AssessmentRenal physiologyAmbulatoryLinear ModelsKidney Failure ChronicCalciumbusinessKidney diseaseNephron
researchProduct

Continuous ambulatory peritoneal dialysis and clinical outcomes in patients with refractory congestive heart failure.

2012

A B S T R A C T Introduction and objectives: Peritoneal dialysis has been proposed as a therapeutic alternative for patients with refractory congestive heart failure. The objective of this study was to assess its effect on long-term clinical outcomes in patients with advanced heart failure and renal dysfunction. Methods: A total of 62 patients with advanced heart failure (class III/IV), renal dysfunction (glomerular filtration<60 mL/min/1.73 m 2 ), persistent fluid congestion despite loop diuretic treatment and at least 2 previous hospitalizations for heart failure were invited to participate in a continuous ambulatory peritoneal dialysis program. Of these, 34 patients were excluded and adj…

Malemedicine.medical_specialtymedicine.drug_classEndpoint Determinationmedicine.medical_treatmentDrug ResistanceUltrafiltrationPeritoneal dialysisCohort StudiesPeritoneal Dialysis Continuous AmbulatoryRisk FactorsInternal medicineClinical endpointmedicineRisk of mortalityHumansProspective StudiesPropensity ScoreAgedHeart Failurebusiness.industryContinuous ambulatory peritoneal dialysisHazard ratioGeneral MedicineLoop diureticmedicine.diseaseSurvival AnalysisConfidence intervalSurgeryTreatment OutcomeHeart failureCardiologyFemalebusinessFollow-Up StudiesRevista espanola de cardiologia (English ed.)
researchProduct

Refractory congestive heart failure: when the solution is outside the heart

2020

Abstract Refractory congestive heart failure is associated with an ominous prognosis in which the treatments strategies remain scarce and not well validated. In the last years, continuous ambulatory peritoneal dialysis (CAPD) has emerged as a therapeutic alternative in this subset of patients. So far, it has been associated with a significant improvement in functional capacity and quality of life, together with a striking reduction in the risk of readmissions. We present the case of an elderly patient with severe left ventricular dysfunction and severe mitral and tricuspid regurgitation who presents recurrent admissions for anasarca. After its inclusion in a CAPD programme, the patient expe…

Malelcsh:Diseases of the circulatory (Cardiovascular) systemmedicine.medical_specialtymedicine.medical_treatmentPeritoneal dialysisCase ReportRegurgitation (circulation)030204 cardiovascular system & hematologyAnasarcaVentricular Function LeftPeritoneal dialysis03 medical and health sciences0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryQuality of lifeRefractoryInternal medicinemedicineHumans030212 general & internal medicineAgedHeart Failurebusiness.industryContinuous ambulatory peritoneal dialysismedicine.diseaseTricuspid Valve InsufficiencyTreatmentRefractory congestive heart failureEchocardiographylcsh:RC666-701Heart failureQuality of LifeCardiologymedicine.symptomDiureticCardiology and Cardiovascular MedicinebusinessESC Heart Failure
researchProduct

CAPD + hemoperfusion once a week in the management of children with end-stage renal disease

1983

With hemoperfusion there is a sharp decline in the solute concentration of the blood compartment, but immediately after HP the concentration of these substances rises to the original level (post-Hp rebound). It may be inferred that the result would be better and the rebound phenomenon less marked if hemoperfusion could be combined with a continuous dialysis system such as CAPD. The study was performed in 3 children of our CAPD programm. All patients were dialysed with 5 daily exchange each of one liter. The patients underwent at 2-hours hemoperfusion with a charcoal column (Gambro Adsorba 150 c) once a week. The data obtained with this form of treatment are indicative for a: significant in…

Malemedicine.medical_specialtymedicine.medical_treatment030232 urology & nephrologyBiomedical EngineeringUrologyMedicine (miscellaneous)Bioengineering030204 cardiovascular system & hematologyEnd stage renal diseasePeritoneal dialysisBiomaterials03 medical and health scienceschemistry.chemical_compound0302 clinical medicinePeritoneal Dialysis Continuous AmbulatoryHumansMedicinePlatelet activationChildIntensive care medicineDialysisCreatininebusiness.industryLiterGeneral MedicineHemoperfusionUric AcidHemoperfusionchemistryCreatinineKidney Failure ChronicUric acidFemalebusinessPeritoneal Dialysis
researchProduct

Vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis in patients with peritonitis.

2011

The aim of this study was to define a two-compartments pharmacokinetic model and to estimate the pharmacokinetic parameters of IP administered vancomycin in patients with continuous ambulatory peritoneal dialysis (CAPD) associated peritonitis. Ten patients with peritoneal dialysis treatment and peritonitis were prospectively enrolled in the study. The empiric treatment is: vancomycin 2 g every 5-7 days and ceftazidime 1500 mg per exchange, once daily. Pharmacokinetic modeling and parameter calculations were carried out using the nonlinear regression. The mean peritoneal concentration 10 min after the first peritoneal exchange of vancomycin free dialysis liquid was 9.5±7.3 μg/ml, showing tha…

Malemedicine.medical_specialtymedicine.medical_treatmentUrologyPharmaceutical SciencePeritonitisPeritonitisCeftazidimePeritoneal dialysisPharmacokineticsPeritoneal Dialysis Continuous AmbulatoryVancomycinmedicineHumansDialysisAntibacterial agentAgedbusiness.industryContinuous ambulatory peritoneal dialysisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsAmbulatoryVancomycinFemalebusinessInjections Intraperitonealmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct

Lipoprotein a) levels in end-stage renal failure and renal transplantation

1993

Some previous studies have documented an increase in lipoprotein (a) [Lp(a)] levels in renal diseases. Here, we report data in subjects with end-stage renal failure treated with hemodialysis (HD) or with continuous ambulatory peritoneal dialysis (CAPD) and in renal transplant recipients (RTR), compared with a group of normolipidemic controls (C). Lp(a) levels were significantly increased in HD and CAPD patients in comparison with C, while they were only slightly increased in RTR. Both HD and CAPD patients showed Lp(a) levels higher than in RTR, but no difference was found between the subjects of the two dialysis procedures. The prevalence of Lp(a) levels > 25 mg/dl was significantly higher …

AdultMalemedicine.medical_specialtymedicine.medical_treatmentUrologyurologic and male genital diseasesNephropathyPeritoneal dialysisPeritoneal Dialysis Continuous AmbulatoryRenal DialysisRisk FactorsHumansMedicineAgedKidneybiologybusiness.industryContinuous ambulatory peritoneal dialysisLipoprotein(a)Middle Agedmedicine.diseaseKidney TransplantationSurgeryTransplantationmedicine.anatomical_structureCardiovascular Diseasesbiology.proteinKidney Failure ChronicFemaleHemodialysisbusinessLipoprotein(a)Lipoprotein
researchProduct